TCGA-MN-A4N1-01A-11R-A24X-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.220
- KRAS_SIGNALING_DN+0.220
- SPERMATOGENESIS+0.220
- MYOGENESIS+0.200
- ESTROGEN_RESPONSE_LATE+0.060
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.050
- ESTROGEN_RESPONSE_EARLY+0.040
- BILE_ACID_METABOLISM+0.030
- ANGIOGENESIS+0.020
- APICAL_JUNCTION+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- MYC_TARGETS_V1-0.480
- INTERFERON_GAMMA_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.400
- MTORC1_SIGNALING-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.390
- IL6_JAK_STAT3_SIGNALING-0.380
- PI3K_AKT_MTOR_SIGNALING-0.360
- PROTEIN_SECRETION-0.360
- ANDROGEN_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-KQ-A41N-01A-11R-A33J-07 | — | — | 0.936 |
| 2 | TCGA-DK-A3IL-01A-11R-A20F-07 | — | — | 0.908 |
| 3 | SRR1335254 | GTEX | — | 0.888 |
| 4 | SRR33346947 | — | — | 0.884 |
| 5 | TCGA-J2-A4AD-01A-11R-A24H-07 | — | cohortA1 | 0.882 |
| 6 | SRR1406561 | GTEX | — | 0.879 |
| 7 | MNG1044 | — | — | 0.878 |
| 8 | SRR602927 | GTEX | — | 0.878 |
| 9 | SRR1432343 | GTEX | — | 0.877 |
| 10 | ERR4976607 | — | B | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |